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Abstract Availability of a rapid, accurate, and reliable
point-of-care (POC) device for detection of infectious
agents and pandemic pathogens, such as swine-origin
influenza A (H1N1) virus, is crucial for effective patient
management and outbreak prevention. Due to its ease of
use, rapid processing, and minimal power and laboratory
equipment requirements, the lateral-flow (immuno)assay
(LFA) has gained much attention in recent years as a
possible solution. However, since the sensitivity of LFA has
been shown to be inferior to that of the gold standards of
pathogen detection, namely cell culture and real-time PCR,
LFA remains an ineffective POC assay for preventing
pandemic outbreaks. A practical solution for increasing the
sensitivity of LFA is to concentrate the target agent in a
solution prior to the detection step. In this study, an aqueous
two-phase micellar system comprised of the nonionic
surfactant Triton X-114 was investigated for concentrating
a model virus, namely bacteriophage M13 (M13), prior to
LFA. The volume ratio of the two coexisting micellar
phases was manipulated to concentrate M13 in the top,
micelle-poor phase. The concentration step effectively
improved the M13 detection limit of the assay by tenfold
from 5×10
8 plaque forming units (pfu)/mL to 5×10
7 pfu/
mL. In the future, the volume ratio can be further
manipulated to yield a greater concentration of a target
virus and further decrease the detection limits of the LFA.
Keywords Lateral-flow immunoassay.Aqueous two-phase
micellar systems.Point-of-care.Viral concentration
and detection.Diagnostics
Introduction
The recent outbreak of swine-origin influenza A (H1N1) virus
infection [1] highlighted the need for a means to rapidly and
accurately detect infectious agents and pandemic pathogens
at the point-of-care (POC), which in turn could result in
better patient management, such as timely use of appropriate
antiviral treatments and isolation of confirmed cases, to aid
in preventing outbreaks [2, 3]. One detection method that has
gained much attention in recent years due to its ease of use,
rapid time to result, and minimal power and laboratory
equipment requirements is the lateral-flow (immuno)assay
(LFA). LFA utilizes a test strip that collects a sample through
lateral flow, and detects the presence of a target molecule
through its specific antibody labeled with a colorimetric
indicator. While LFA has been used to detect a wide range of
biomolecules [4], its sensitivity in detecting viruses has been
shown to range from 19% to 96% compared to the gold
standards, namely viral culture and real-time PCR [3, 5–9].
Although LFA is superior to viral culture and real-time PCR
in terms of ease of use and rapid time to result, its typically
low sensitivity in detecting pathogens and viruses limits its
effectiveness as a reliable POC assay for preventing
pandemic outbreaks. Therefore, the sensitivity of LFA for
detection of infectious viruses must first be improved before
i tc a nr e l i a b l yb eu s e da sa ne f f e c t i v eP O Cs o l u t i o n .
One approach to achieve a higher sensitivity for LFA is
to improve the assay itself. Another approach is to
concentrate the target biomolecule prior to the detection
step. The focus of this work is on the latter approach, and
Electronic supplementary material The online version of this article
(doi:10.1007/s00216-010-4213-7) contains supplementary material,
which is available to authorized users.
F. Mashayekhi: R. Y. T. Chiu: A. M. Le: F. C. Chao:
B. M. Wu: D. T. Kamei (*)
Department of Bioengineering, University of California,
5121 Engineering V, 420 Westwood Plaza,
Los Angeles, CA 90095-1600, USA
e-mail: kamei@seas.ucla.edu
Anal Bioanal Chem (2010) 398:2955–2961
DOI 10.1007/s00216-010-4213-7we investigated concentrating a target virus using an
aqueous two-phase system (ATPS) prior to its detection
via LFA. Although ATPS have also been previously
studied, the work reported here is novel and significant,
since it represents the first time the established technologies
of LFA and ATPS have been combined. In fact, ATPS,
which can be formed with micelles (aqueous two-phase
micellar system, ATPMS), polymers, or a combination of
the two, have generally been examined for large-scale
biotechnological applications [10–16] and not small-scale
diagnostic applications. ATPS are very appropriate for a
POC device, since they are easy to use, can be rapid, and
are scalable (to require minimal sample volume). Further-
more, ATPS also do not require any laboratory equipment
and are low in cost compared to chromatography [17–19].
In this proof-of-principle study, an ATPMS comprised of
the nonionic surfactant Triton X-114 and phosphate-buffered
saline(PBS) was investigatedfor concentratinga modelvirus,
namely bacteriophage M13 (M13). In an aqueous solution at
concentrations above their critical micelle concentration, the
surfactant molecules form micelles [20]. The Triton X-114
micellar system exhibits a homogeneous, isotropic phase at
low temperatures. Upon increasing the temperature, the
solution undergoes a macroscopic phase separation to yield
a top, micelle-poor phase and a bottom, micelle-rich phase.
Biomolecules would then distribute, or partition, unevenly
between the two phases based on their physico-chemical
characteristics, such as hydrophobicity [21] and size [22].
First, we wanted to gain an understanding of the main
driving forces for M13 partitioning in the Triton X-114
micellar system to assess the predictability of the M13
partitioning behavior. Accordingly, the experimentally mea-
sured partitioning behavior of M13 was compared with our
theoretical predictions based on a model developed recently
for the partitioning of cylindrical biomolecules in ATPMS
[16]. Next, M13 was concentrated in the top, micelle-poor
phase by manipulating the volume ratio (the volume of the
top, micelle-poor phase divided by that of the bottom,
micelle-rich phase). After ensuring that we could concentrate
M13 in the ATPMS in a predictive manner, we developed an
LFA for the detection of M13 in-solution. Once the detection
limit of the immunoassay was established, M13 was
concentrated by utilizing the ATPMS prior to the detection
step to investigate the effect of the concentration step on the
immunoassay’s detection limit.
Materials and methods
Culturing and quantifying M13
Escherichia coli bacteria (American Type Culture Collec-
tion, ATCC, Manassas, VA) were incubated in 6 mL of
lysogeny broth (10 g/L tryptone (BD, Franklin Lakes, NJ),
5 g/L yeast extract (BD), and 10 g/L NaCl) at 37 °C and
240 rpm in a shaker incubator for 12 h. In order to culture
M13 (ATCC), 10 μL of the stock M13 solution was added
to the cultured bacteria solution. The bacteria solution was
then incubated in a shaker incubator at 37 °C and 240 rpm
for 5 h. The solution was then centrifuged at 4 °C and
8,000×g for 15 min to remove the bacteria. The supernatant
containing M13 was collected and filtered using a 0.22 μm
syringe filter (Millipore, Billerica, MA).
As described previously [23], the plaque assay was used
to quantify the concentration of M13 in-solution, and
therefore, the concentration of M13 is reported as plaque
forming units (pfu) per mL. All reagents and materials were
purchased from Sigma-Aldrich (St. Louis, MO) unless
otherwise noted.
Partitioning and concentrating M13
For each M13 partitioning experiment, three identical
3.5 mL Triton X-114 solutions in Dulbecco’s PBS (Invi-
trogen, pH 7.4, containing 1.47 mM KH2PO4, 8.10 mM
Na2HPO4, 137.93 mM NaCl, 2.67 mM KCl, and 0.49 mM
MgCl2) were prepared. M13 was added to the solutions at a
concentration of 10
8 pfu/mL. In order to ensure that each
solution is in one phase prior to phase separation, the
solutions were equilibrated at 4 °C prior to the addition of
M13. Once M13 was added, the solutions were mixed and
placed in a water bath set at the appropriate temperature
which yielded a volume ratio equal to approximately 1. The
operating conditions (i.e., temperature and initial surfactant
concentration) are listed in Table S1 in the Electronic
Supplementary Material. After incubating the three solu-
tions in the water bath for 18 h, the two coexisting micellar
phases were withdrawn carefully using syringe and needle
sets, and the concentration of M13 in each of the two
phases was determined using the plaque assay. Each
partitioning experiment, which involved triplicate solutions,
was repeated at least twice.
By altering the volume ratio of the partitioning experi-
ments, M13 can be concentrated in the top, micelle-poor
phase. The same protocol described above for partitioning
M13 was used, except that the initial Triton X-114
surfactant concentrations and operating temperatures were
varied in order to achieve the desired volume ratios. The
operating conditions and resulting volume ratios are listed
in Table S2 in the Electronic Supplementary Material.
Preparing colloidal gold probes
The colloidal gold nanoparticles were prepared according to
Frens [24]. The colloidal gold-antibody probe was prepared
as described by Horisberger and Clerc [25]. Briefly, the pH
2956 F. Mashayekhi et al.of a 2.5-mL colloidal gold nanoparticle solution was adjusted
to pH 9 using 0.1 M NaOH. Subsequently, 40 μgo fa n t i - M 1 3
mousemonoclonalantibody(AbcamInc.,Cambridge,MA)at
a concentration of 0.2 mg/mL was added to the colloidal gold
solution and mixed for 10 min on a shaker. To prevent
nonspecific binding of other proteins to the surfaces of the
colloidal gold nanoparticles, 250 μLo f1 0 %w/v bovine
serum albumin (BSA) was added to the mixture and mixed
for 15 min on a shaker to block all excess surfaces on the
colloidal gold nanoparticles. The mixture was then centri-
fuged for 30 min at 4 °C and 9,000×g to remove free
antibody and BSA. The pellet, which contained the colloidal
gold nanoparticles, was resuspended in 375 μLo f0 . 1M
sodium borate buffer, pH 9.
Preparing LFA test strips
There are two different approaches for the LFA: the
sandwich assay and the competition assay. In this study,
we implemented the sandwich assay. As shown schemati-
cally in Fig. 1, in the sandwich assay, antibodies specific for
the target of interest are immobilized on a nitrocellulose
membrane in the form of a line, called the test line.
Secondary antibodies against the primary antibody are also
immobilized on the nitrocellulose membrane in the form of
a line, called the control line. In LFA, a sample first comes
into contact with the colloidal gold probes. If the target
molecules are present in the sample, they would first bind
to their specific antibodies immobilized on the colloidal
gold nanoparticles. Subsequently, as the colloidal gold
nanoparticles move up the LFA strip, the target molecules
present in the colloidal gold-antibody-target molecule
complexes would bind to their specific antibodies immobi-
lized on the test line. Due to the presence of “trapped”
colloidal gold particles, which exhibit a purplish red color,
a visual band is formed at the test line that indicates a
positive result (Fig. 1a). Alternatively, if the target molecule
is not present in the solution, the colloidal gold-complexed
antibodies would not be “trapped” by the immobilized
antibodies at the test line. This indicates a negative result
(Fig. 1b). Furthermore, regardless of the presence of the
target molecule in the sample, colloidal gold-complexed
antibodies would bind and get “trapped” by the immobi-
lized secondary antibodies on the control line, which
indicates a valid test. The LFA test strips used in this study
were prepared using a similar approach to that of Schuurs
and coworkers [26].
Performing LFA on M13
The operating condition that was used for performing the
concentration step prior to the detection step resulted in
M13 being concentrated in the top, micelle-poor phase with
a Triton X-114 concentration of 0.065% w/w in PBS.
Therefore, to be consistent between the immunoassays
performed with or without the concentration step, solutions
of M13 in 0.065% w/w Triton X-114 in PBS were used to
perform the LFA without the concentration step. The LFA
was performed as follows: Solutions containing varying
M13 concentrations diluted in 0.065% w/w Triton X-114 in
PBS were first prepared. Forty-five microliters of the M13
solutions were then added to 10 μL of the colloidal gold
probes solution and 25 μL of test buffer (0.2% BSA, 0.3%
Tween20, 0.2% sodium azide, 0.1% polyethylene glycol,
0.1 M Trizma base, pH 8), which was used to facilitate the
flow of the samples through the test strips. The resulting
solutions were mixed, and incubated for 5 min before a test
strip was dipped vertically into each solution so that only
the sample pad would come in contact with the solution.
After 20 min, the test strips were taken out of the solution,
and an image of each strip was immediately taken by a
Canon EOS 1000D camera (Canon U.S.A., Inc., Lake
Success, NY).
Combining ATPMS with LFA
To combine the concentration step with the detection step,
M13 was first concentrated following the same protocol as
mentioned previously in Partitioning and Concentrating
M13. Solutions containing 9.50% w/w Triton X-114 in PBS
were used, and the solutions were incubated at 26.0 °C for
18 h. At these operating conditions, a volume ratio of 1/9
(0.111) was obtained. In addition, various amounts of M13
were added to each solution to obtain appropriate initial
concentrations of M13. After phase separation, the top
phases were withdrawn carefully using syringe and needle
sets. The LFA was performed as described in Performing
LFA on M13, except instead of using 45 μL of the M13
solutions diluted in 0.065% w/w Triton X-114 in PBS, 45 μL
of the withdrawn top, micelle-poor phases were used.
Fig. 1 Schematic representations of a positive and b negative results
for the LFA using the sandwich mechanism
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Partitioning M13 in ATPMS
The partitioning behavior of a biomolecule in an ATPMS is
quantified by evaluating the partition coefficient, Kbm,
which is defined as follows:
Kbm  
Cbm;t
Cbm;b
ð1Þ
where Cbm,t and Cbm,b are the concentrations of the
biomolecule in the top and bottom phases, respectively. Based
onitsshape,M13canbemodeledasacylindricalbiomolecule.
Wehadpreviouslyextendedamodel,whichwasdevelopedby
Blankschtein and coworkers [22, 27] for the partitioning of
spherical, water-soluble proteins in ATPMS, to cylindrical
biomolecules (cb). This model incorporates the repulsive,
steric, excluded-volume interactions that operate between the
cylindrical biomolecule and the cylindrical micelles, and the
following expression was derived for the partition coefficient
of a cylindrical biomolecule, such as M13 [16]:
KEV
cb ¼ exp   ft   fb ðÞ 1 þ
lcbR2
cb
lmR2
m
þ
1
2
Rm lm þ Rm ðÞ lcb þ pRcb ðÞ þ Rcb lcb þ Rcb ðÞ lm þ pRm ðÞ
lmR2
m
   
ð2Þ
where Φt and Φb are the surfactant volume fractions in the
top and bottom phases, respectively, Rcb and Rm are the
cross-sectional radii of the biomolecule and micelles,
respectively, and lcb and lm are the lengths of the
biomolecule and micelles, respectively. The cross-
sectional radius of M13 was estimated to be 7 nm, and its
length was estimated to be 900 nm [28]. The cross-sectional
radius of Triton X-114 micelles was estimated to be 23.4 Å
[16], while their lengths were estimated to be between
10 nm and 1 μm[ 29–33]. Based on Eq. 2, the values for
the dimensions of M13 and Triton X-114 micelles, and the
one-to-one correspondence between operating temperature
and (Φt–Φb) found previously [16], extremely large
(>>1,000) M13 partition coefficients as a function of
temperature were predicted. However, as shown previously
for the partitioning behavior of DNA fragments and
spherical viruses in ATPMS [16, 34], the entrainment of
micelle-poor domains in the macroscopic micelle-rich
phase has a significant impact on the partitioning behavior
of such large hydrophilic macromolecules.
Due to the small density difference and interfacial
tension between the micelle-rich and micelle-poor domains,
macroscopic phase separation equilibrium is not attained
even after waiting a long time. As a result, some micelle-
poor domains are entrained in the macroscopic micelle-rich
phase, and similarly, some micelle-rich domains are
entrained in the macroscopic micelle-poor phase. If M13
partitions extremely into the micelle-poor domains, as
predicted by the model, the concentration of M13 in the
micelle-poor domains would be orders-of-magnitude great-
er than that in the micelle-rich domains. Therefore, the
effect of entrained micelle-poor, M13-rich domains on the
measured concentration of M13 in the macroscopic,
micelle-rich, M13-poor phase would be drastic, while the
effect of entrained micelle-rich, M13-poor domains on the
measured concentration of M13 in the macroscopic,
micelle-poor, M13-rich phase would be negligible. Defin-
ing x as the volume fraction of micelle-poor domains
Fig. 2 a Experimentally measured partition coefficients for M13 at
various temperatures, and b comparison of experimentally measured
(filled square) and theoretically predicted (solid line) M13 concentra-
tion factors for various volume ratios. Error bars represent standard
deviations from at least three measurements
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the newly predicted partition coefficient could be written as
follows [16, 34]:
KEVþEnt
M13 ¼
KEV
M13
1 þ x  ð KEV
M13   1Þ
ð3Þ
where KEV
M13 is the partition coefficient of M13 based only
on excluded-volume interactions. For large values of KEV
M13,
as in the case of M13 in ATPMS, Eq. 3 simplifies to:
lim
KEV
M13!1
KEVþEnt
M13  
1
x
ð4Þ
Equation 4 indicates that the partition coefficient of M13
should only be dependent on x. It has also been shown by
Blankschtein and coworkers that x is only a function of the
volume ratio [34]. Therefore, if the volume ratio is
maintained at 1 for all temperatures, the measured partition
coefficients for M13 should not change by varying the
operating temperature. Figure 2a shows the partition
coefficients of M13 obtained experimentally at various
operating temperatures, while the volume ratio was main-
tained at approximately 1. As expected and shown in
Fig. 2a, the partitioning behavior of M13 in the aqueous
two-phase Triton X-114 micellar system is fairly insensitive
to the operating temperature, suggesting that M13 parti-
tioning is driven by the excluded-volume interactions
between M13 and micelles, but is limited by entrainment.
Nevertheless, since the measured values of the M13
partition coefficients are much greater than 1, they can still
be exploited as described below.
Concentrating M13 by manipulating the volume ratio
In an approach similar to that developed previously [10],
the concentration factor, that is, the concentration of the
virus in the top phase divided by the initial concentration,
can be expressed by using the following equation [16]:
concentration factor  
CM13;t
CM13;0
¼
Vt
Vb þ 1
Vt
Vb þ 1
Km
M13
ð5Þ
where Vt and Vb are the volumes of the top and bottom
phases, respectively, CM13,0 is the initial concentration of
M13 in the homogeneous micellar solution prior to phase
separation, CM13,t is the concentration of M13 in the top
phase, and Km
M13 is the measured partition coefficient. For
large values of Km
M13, the concentration factor could be
approximated as follows:
concentration factor   1 þ
1
Vt
Vb
ð6Þ
Based on Eq. 6, and the large values of Km
M13 obtained
experimentally (Fig. 2a), the concentration factor can be
manipulated by simply varying the volume ratio. Therefore,
the volume ratio was varied from 1 to approximately 1/
8 (0.121), and a two- to sevenfold concentration of M13 in
the top phase was achieved (Fig. 2b). In addition, as
indicated in Fig. 2b, there is reasonable agreement between
the experimentally measured concentration factors and the
predictions obtained from Eq. (6).
Detecting M13 via LFA
After demonstrating that M13 could be concentrated via an
ATPMS, we prepared colloidal gold probes and LFA test
strips by utilizing goat polyclonal anti-mouse IgG antibody
and mouse monoclonal antibody to M13’s coat protein
pVIII. Figure 3 shows the LFA results. As mentioned
previously, the presence of the top line, which contains
immobilized goat polyclonal anti-mouse IgG antibody,
indicates a valid test. The presence of the lower test line,
which contains mouse monoclonal antibody to M13’s coat
protein pVIII, indicates the presence of M13. As indicated
in Fig. 3, while no test line appeared for the negative
Fig. 3 LFA used to detect M13 without a prior concentration step.
The negative control without any M13 is shown in panel a. The
remaining solutions contained M13 at concentrations of b 1×10
10, c
5×10
9, d 1×10
9, e 5×10
8, and f 1×10
8 pfu/mL
Fig. 4 LFA used to detect M13
with the prior concentration
step. The negative control with-
out any M13 is shown in panel
a. The remaining solutions
initially contained M13 at con-
centrations of b 1×10
10, c 5×
10
9, d 1×10
9, e 5×10
8, f 1×10
8,
g 5×10
7, and h 1×10
7 pfu/mL
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of the test line decreased with the decreasing concentration of
M13 until the test line was no longer present for the solution
containing 10
8 pfu/mL (Fig. 3f). This indicated a detection
limit of approximately 5×10
8 pfu/mL for the M13 LFA
performed without a prior concentration step.
Concentrating M13 prior to LFA
After establishing the detection limit, we investigated the
possible improvement of the detection limit if M13 were to
be concentrated by utilizing an ATPMS prior to the
detection step. To do so, 9.50% w/w Triton X-114 in PBS
solutions with different initial concentrations of M13 were
incubated at 26.0 °C for 18 h. At these operating
conditions, a volume ratio of 1/9 was obtained, and based
on Eq. 6, an approximately tenfold concentration of M13 in
the top, micelle-poor phase was predicted. After phase
separation, the top, micelle-poor, M13-rich phases were
withdrawn using syringe and needle sets, and were
consequently used in the LFA. The results of the LFA with
the prior concentration step are shown in Fig. 4. While no
test line appeared for the negative control solution, which
did not contain any M13, the intensity of the test line
decreased with the decreasing concentration of M13 until
the test line was no longer present for the solution
containing 10
7 pfu/mL (Fig. 4h). This indicated a detection
limit of approximately 5×10
7 pfu/mL for the M13 LFA
when combined with the prior concentration step, which
represented a tenfold improvement of the detection limit of
the LFA assay. Furthermore, the intensity of the test line for
all of the detectable concentrations clearly increased when
the concentration step was incorporated prior to the
detection step. It should be noted that, in this proof-of-
concept study, a volume ratio of only 1/9 was utilized to
demonstrate the improvement of the concentration step on
LFA’s detection limit. In the future, even lower volume
ratios may be implemented to yield greater concentration
factors that can lead to even lower detection limits.
Furthermore, while phase separation of an ATPS could be
sped up via low-speed centrifugation [35], since the
ultimate goal of this approach is to enhance the detection
of pathogens at the point-of-care without using any
laboratory equipment, other ATPS could instead be utilized
and optimized to achieve rapid separation within the time
frame of typical LFA diagnostic tests without the need for
centrifugation.
Conclusions
Concentrating infectious agents, such as infectious viruses,
prior to LFA could significantly increase the effectiveness
of using LFA for patient management at the POC. This study
demonstrated this approach by the novel combination of an
ATPMS with LFA to improve the detection limit of
bacteriophage M13. The micellar system was generated using
the nonionic surfactant Triton X-114 and PBS. We first
compared experimentally measuredpartition coefficientswith
our theoretical predictions obtained from a model developed
previously for cylindrical biomolecules. The agreement
between theory and experiment indicated that the partitioning
behavior of M13 in the nonionic micellar system is primarily
driven by repulsive, steric, excluded-volume interactions that
operate between the micelles and M13 particles, but is limited
by the entrainment of micelle-poor, M13-rich domains in the
macroscopic, micelle-rich phase. Next, the volume ratio was
manipulated to concentrate M13 particles in the top phase. By
decreasing the volume ratio from 1 to 1/8, M13 particles were
concentrated in the top phase two- to sevenfold in a predictive
manner. After demonstrating that we could concentrate M13
intheATPMS,wedevelopedanLFAforthedetectionofM13
in-solution. The detection limit of the M13 LFA itself was
found to be 5×10
8 pfu/mL. M13 was subsequently concen-
trated approximately tenfold by utilizing the ATPMS, which
led to a tenfold improvement in the LFA detection limit to
5×10
7 pfu/mL. Therefore, we demonstrated proof-of-
principle that concentrating a target virus with ATPS prior
to the detection step enhances the detection limit of the LFA,
thereby increasing the sensitivity of the immunoassay. In the
future, the operating conditions could be manipulated to
obtain even lower volume ratios, which in turn should result
in obtaining higher concentration factors that yield even
lower detection limits. Furthermore, the ATPS utilized could
be optimized to achieve rapid phase separation within the
time frame of typical LFA diagnostic tests, so that the
complete detection assay, including the concentration step,
could be completed within an hour. We believe once
optimized, the novel approach of utilizing ATPS to concen-
trate target molecules, such as infectious viruses, prior to the
detection step could significantly improve the sensitivity of
LFA, which in turn could enhance its effectiveness as a POC
solution for preventing pandemic outbreaks.
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